A phase 3 trial of Aldeyra Therapeutics’ dry eye disease prospect has hit its primary endpoint, preparing the biotech to seek approval for a candidate the FDA has rejected twice in recent years.

Researchers at Aston University have called for more advice to be given to young people about preventing dry eye disease, after a study carried out in conjunction with Oslo University Hospital and ...

Reproxalap 0.25% was superior to vehicle-control on ocular discomfort symptom score from 80 to 100 minutes after chamber entry. Reproxalap ophthalmic solution 0.25% reached the primary endpoint in ...

It can be difficult to diagnose dry eye properly because it’s one of many conditions that can make your eyes feel dry or uncomfortable. Consulting a qualified ophthalmologist or optometrist can ...

Dry eye occurs when your eyes do not produce enough tears to stay properly lubricated. Primary treatment options include artificial tears and prescription eye drops. However, if they don’t help ...

If you’re one of the millions of people who have persistently dry eyes, you know that dry eye syndrome can be a nuisance. But the condition, which happens when your tears don’t lubricate your ...

Reproxalap is an investigational new drug candidate in development for the treatment of dry eye disease and allergic conjunctivitis, two of the largest markets in ophthalmology. Reproxalap is a ...

A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to ...

For instance, some researchers found that blue light can lead to: Irritation or strain Increased sensitivity Dry eye syndrome, a condition that causes the eyes to make fewer tears Cataracts ...